EGFR and breast carcinoma: In accordance with our findings, previous studies have suggested that inhibiting EGFR palmitoylation with 2-BP could decrease EGFR PM localization, reduce EGFR protein expression, and sensitize lung and breast cancer cells to EGFR-targeted tyrosine kinase inhibitors (TKIs) treatments [41, 61].